FDA Approves Gemtesa for Overactive Bladder in Men With BPH
Gemtesa approved for men with overactive bladder symptoms receiving pharmacologic treatment for benign prostatic hyperplasia
Prebiopsy MRI Oncologically Safe for Suspected Prostate Cancer
Men with negative mpMRI results avoiding biopsy did not have increased risk for clinically significant prostate cancer
Modest Decline Seen in Portal Messaging With Billing Implementation
8.8 percent decrease seen in volume of patient-initiated medical advice message threads in six months after implementation
U.S. Health Care Spending Reached $4.9 Trillion in 2023
Health sector's share of the economy was similar in 2023 and 2022, but lower than in 2020 and 2021, during height of COVID-19
2000 to 2024 Saw Rise in Physician Union Petitions
Most organizing efforts motivated by nonfinancial factors
Fish Oil Supplementation Cuts Measure of Prostate Cancer Progression
Findings seen among men enrolled in one year of active surveillance
Prostate Cancer Incidence, Mortality Rates Mainly Stable, Decreasing
Increases seen in some countries, mostly in Africa, Asia, Latin America and the Caribbean, and Central and Eastern Europe
Screening Primary Driver of Averted Cancer Deaths From 1975 to 2020
Authors say further reductions will require new discoveries, adoption of emerging interventions
7.9 Percent of People of All Ages Uninsured in January to June 2024
No change seen in percentage of people who were uninsured from 2023 to first half of 2024; lower percentage had public coverage
Comparable Results Seen for HoLEP With, Without Preservation of Urethral Mucosa in BPH
HoLEP with and without preservation of the urethral mucosa from bladder neck to the tip of the prostate yielded similar efficacy, safety
